Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage III deficient mismatch repair colon cancer, according to findings presented ...

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

Atezolizumab plus mFOLFOX6 is a practice-changing and new standard treatment for patients with dMMR stage III colon cancer,” said Frank Sinicrope, MD.

The IMforte trial showed improved progression-free survival and overall survival with lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer. The trial's primary analysis ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...